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Purpose: To investigate to what degree the presence of hypertension (HTN) and poor glycemic
control (GC) influences the likelihood of having microalbuminuria (MAU) among Cuban
Americans with type 2 diabetes (T2D).
Methods: A cross-sectional study conducted in Cuban Americans (n = 179) with T2D.
Participants were recruited from a randomly generated mailing list purchased from KnowledgeBase Marketing, Inc. Blood pressure (BP) was measured twice and averaged using an adult
size cuff. Glycosylated hemoglobin (A1c) levels were measured from whole blood samples
with the Roche Tina-quant method. First morning urine samples were collected from each
participant to determine MAU by a semiquantitative assay (ImmunoDip).
Results: MAU was present in 26% of Cuban Americans with T2D. A significantly higher percentage of subjects with MA had HTN (P = 0.038) and elevated A1C (P = 0.002) than those with
normoalbuminuria. Logistic regression analysis showed that after controlling for covariates,
subjects with poor GC were 6.76 times more likely to have MAU if they had hypertension compared with those without hypertension (P = 0.004; 95% confidence interval [CI]: 1.83, 23.05).
Conclusion: The clinical significance of these findings emphasizes the early detection of MAU
in this Hispanic subgroup combined with BP and good GC, which are fundamentals in preventing and treating diabetes complications and improving individuals’ renal and cardiovascular
outcomes.
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In past years, numerous studies have described the role of microalbuminuria (MAU)
as a predictor of cardiovascular disease (CVD) and death among subjects with
type 2 diabetes (T2D).1–3 MAU is one of the earliest clinical signs for diabetic
nephropathy and a significant risk factor for progression to proteinuria.1 Additionally,
hypertensive T2D individuals with MAU have an increased risk of developing endstage renal disease (ESRD).4 Risk factors known to be associated with CVD and
diabetic nephropathy are high blood pressure (BP) and elevated glycosylated
hemoglobin (A1c).5,6 Achieving adequate BP and glycemic control (GC) plays an
essential role in preventing renal and CVD events in individuals with T2D.
A current secondary analysis from the Hispanic Health and Nutritional Examination Survey (HHANES)7 indicated that Cuban Americans have higher serum cholesterol
and systolic BP than Puerto Ricans and Mexican Americans. Furthermore, compared
with other Hispanic subgroups, Cuban Americans have the highest proportion of
hypertension (HTN) and mean serum creatinine levels.8 Smith and Barnett9 examined
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the National Center for Health Statistics (NCHS) from 1996
to 1997 and concluded that Cuban Americans 35 years of
age and older have the highest percentage of diabetes-related
deaths compared with other Hispanics.
Although previous studies have shown significant
differences and diversity within Hispanics, further studies
conducted in the Cuban American population are scarce.
Over the past decade, the prevalence of T2D has increased,
especially among Cuban Americans who have a higher incidence of diabetes (8.2%) compared with 6.6% of non-Hispanic
Whites.10 The high incidence of T2D combined with an
increased risk for developing diabetes complications warrants
further examination of the Cuban American population.
Screening for MAU can detect individuals at risk for renal
dysfunction and CVD events and possibly reduce the burden
associated with diabetes complications. Therefore, the purpose of this study was to investigate to what degree the
coexistence of HTN and poor GC influences the likelihood
of having MAU among Cuban Americans with T2D. It was
hypothesized that individuals with T2D, HTN, and poor GC
will have an increased likelihood to test positive for MAU. It
was further hypothesized that this association will be stronger
after controlling for confounding variables.

This was a cross-sectional study conducted in Cuban
Americans with and without T2D.

on the phone, at which time the study purpose was explained
and the age and gender of the responders were determined.
To ascertain T2D status, each participant was asked for the
age of diagnosis and initial treatment modalities. Only
18 subjects did not qualify for the study for not being Cuban
Americans (n = 2), age younger than 30 years (n = 9), and
having other chronic illnesses (n = 7). If a subject was determined to be eligible, then their participation was requested at
the Human Nutrition Laboratory at Florida International
University (FIU). Participants were instructed to refrain from
smoking, consuming any food and beverages except water,
and doing any unusual exercise for at least 8 hours prior to
their blood collection. Subjects with T2D were matched for
age and gender with subjects without diabetes. This study
was approved by the Institutional Review Board at FIU. The
purpose and protocol of the study were explained to the subjects, and their written consent, either in Spanish or English,
was obtained prior to the commencement of the study. Seven
participants reported not having diabetes but were reclassified
because their lab results classified them as having T2D
according to American Diabetes Association (ADA) standards. These subjects were given their laboratory results and
referred to their physicians. For the data analysis, subjects
with caloric intakes .5000 kcals (n = 2) and missing A1c
levels (n = 2) were excluded. For two participants, we were
unable to perform A1c analysis. In total, we included only
the data from subjects with T2D (n = 179) who were aged
30 years and older.

Study population

Study variables

Data from a complete sample set of Cuban Americans with
and without T2D were used in the present study. Recruitment
of participants was conducted in alternate phases of potential subjects with and without T2D, age matching subjects by
age groups. During a 1-year period, approximately
10,000 letters outlining the study were mailed to subjects aged
30 years or older with and without diabetes. Letters were sent
in English and Spanish and included an invitation flyer to
which interested participants could respond. The participants
were initially recruited by random selection (every tenth
address) from a randomly generated mailing list. The list of
addresses was purchased from KnowledgeBase Marketing,
Inc., Richardson, TX, USA. This company provided a mailing
list of Cuban Americans identified as with and without T2D
from Miami-Dade and Broward Counties, Florida. Three
percent (n = 300) of the letters were returned due to unknown
addresses. From the remaining delivered mail, 4% (n = 388)
responded. Interested participants were initially interviewed

A sociodemographic questionnaire was given to each
participant to complete, which included questions related to
age, gender, smoking status, medications for diabetes, HTN,
and cholesterol. Height and weight were measured using a
Seca balance scale (Seca Corp, Columbia, MD, USA). Body
mass index (BMI) was calculated as weight in kg/height in
m2. BP was measured twice then averaged in participants in
a sitting position after a 15-minute rest using a random zero
sphygmomanometer (Tycos 5090-02 Welch Allyn Pocket
Aneroid Sphygmomanometer, Arden, NC, USA) and a
stethoscope (Littmann Cardiology, 3M, St Paul, MN, USA).
HTN was defined as follows: systolic BP $ 140 mm Hg systolic
or diastolic BP $ 90 mm Hg or using antihypertensive
treatment.11

Methods
Design
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Dietary assessment
Dietary intake was measured using a validated semiquantitative food frequency questionnaire (FFQ) developed by
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Willett et al.12 This FFQ has also been validated by Nath
and Huffman13 exclusively for the Cuban American population. Participants self-reported average consumption of specified amounts of various foods over the past year and chose
from frequency responses ranging from “never” to “six or
more servings per day”. In addition to food items, the FFQ
included questions about type and duration of vitamin/mineral
supplement use, alcohol consumption, and specific details
about fat, salt, and sugar used in cooking and as condiments.
Macro- and micronutrient intake was calculated by multiplying frequency of consumption by the nutrient value of the
food item obtained from the Harvard University Food Composition Database (Boston, MA, USA).

Blood collection
Venous blood (20 mL) was collected from each subject after an
overnight fast (at least 8 hours) by a certified phlebotomist using
standard laboratory techniques. Blood samples were collected
into a Vacutainer® Serum Separator Tube (SST) (Becton, Dickinson and Company, Franklin Lakes, NJ) for analysis of lipids
and another tube containing ethylenediamine tetraacetic acid to
analyze A1c. After coagulation was completed (30–45 minutes),
the SST was centrifuged at 2500 RPM for 30 minutes. Lipid
panel was assayed by enzymatic methods, and A1c percentages
were measured from whole blood samples with the Roche Tinaquant method by Laboratory Corporation of America, Miami,
FL, USA (LabCorp®). Poor GC was defined according to the
ADA standards (A1c . 7%).14

Urinary albumin
Fresh, single-voided, first morning urine samples were collected from each participant to determine MAU by a semiquantitative assay (ImmunoDip, Diagnostic Chemicals
Limited, Oxford, CT, USA). ImmunoDip Urinary Albumin
Test uses a monoclonal antibody against human serum albumin to detect MAU. The study conducted by Davidson et al15
was designed to evaluate the clinical performance of
the ImmunoDip dipstick compared with a reference
measure recommended by the ADA for detecting MAU
(albumin:creatinine ratio ,30 ug/mg [negative]; .30 ug/mg
[positive]) determined by laboratory techniques (Quest
Hitachi 717 autoanalyzer). Additionally, results from the
ImmunoDip were compared with quantitatively measured
albumin concentrations as a secondary outcome. Urinary
albumin concentrations were considered ,18 mg/L (negative) and .18 mg/L (positive). Screening for MAU with
ImmunoDip exhibited a sensitivity of 96% and specificity of
80% when compared with albumin:creatinine ratio .30 ug/mg.
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When ImmunoDip was examined against quantitatively
measured albumin concentrations, the dipstick yielded a
sensitivity of 95% and specificity of 94%. Recommendations
from the National Academy of Clinical Biochemistry
(NACB) for the diagnosis and management of diabetes indicated that a useful semiquantitative screening test for MAU
should have a sensitivity .95%.16 The ImmunoDip dipstick
fulfilled the requirements from the NACB as a screening tool
to detect MAU. In our study, positive for MAU was defined
as urinary albumin concentrations of .18 mg/L in spot collection. This cut-off value was established by the manufacturer (ImmunoDip, Diagnostic Chemicals Ltd) and
corresponded to albumin:creatinine ratio .30 ug/mg values
for MAU detection.15

Data analysis
All analyses were performed using SPSS Version 17
(SPSS Inc., Chicago, IL, USA). T-tests and Chi-square tests
were performed to compare means and proportion differences between subjects with and without MAU. Unadjusted
odds ratios and logistic regression analysis were conducted
to investigate the extent to which HTN and GC are associated with an increased likelihood of having MAU.
Controlled variables included in the logistic regression
analysis were age, gender, BMI, known duration of
diabetes, total cholesterol levels, diabetes and cholesterol
medications, smoking, total kcal and protein intake, and
intake of potassium, phosphorous, and sodium. The level
of significance was set at P , 0.05.

Results

MAU was present in 26% (n = 47) of Cuban Americans
with T2D. There was a significantly higher percentage of
subjects with MAU classified as hypertensive (P = 0.038)
and taking diabetes medication (P = 0.039) compared with
those without MAU. Additionally, subjects who tested
positive for MAU had significantly higher A1c levels
(P = 0.002) than those with nor moalbuminuria
(Table 1).
Unadjusted odds ratios indicated that subjects with poor
GC were 3.96 times more likely to have positive MAU if
they had HTN compared with those without HTN
(P = 0.014; 95% confidence interval [CI] 1.25, 12.5)
(Figure 1). Logistic regression analysis showed that after
controlling for covariates, subjects with poor GC were
6.76 times more likely to have MAU if they had HTN
compared with those without HTN (P = 0.004; 95% CI
1.83, 23.05) (Table 2).
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Table 1 Characteristics of subjectsa
Cuban Americans with type 2 diabetes

P value

Microalbuminuria

Gender (female/male) (%)
Age (years)
Body mass index (kg/m2)
Waist circumference (cm)
Smoking (%)
Known duration of diabetes (years)
Diabetes medications (%)
Glycosylated hemoglobin (%)
Hypertension medications (%)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Hypertension (%)
Cholesterol medications (%)
Total cholesterol (mg/dL)
Energy intake (kcal)
Protein (g)
Potassium (mg)
Sodium (mg)
Phosphorous (mg)

Positive
(n = 47)

Negative
(n = 132)

53.2/46.8
67.9 ± 12.9
30.5 ± 6.0
105.7 ± 15.0
17.0
10.5 ± 10.1
89.4
8.2 ± 2.0
61.7
133.69 ± 14.5
78.3 ± 9.9
78.7
27.7
188.3 ± 42.8
2212.1 ± 870.0
108.4 ± 44.5
3676.8 ± 1436.5
2208.8 ± 1091.8
1665.7 ± 688.0

64.4/35.6
64.4 ± 11.4
31.9 ± 6.7
105.4 ± 14.6
14.4
8.9 ± 9.5
75
7.4 ± 1.5
52.3
131.48 ± 15.6
80.1 ± 8.4
62.1
18.9
196.7 ± 41.0
2165.4 ± 775.1
105.0 ± 36.4
3756.2 ± 1245.3
2204.4 ± 913.5
1604.6 ± 564.2

0.175
0.083
0.219
0.892
0.666
0.338
0.039
0.002
0.265
0.399
0.225
0.038
0.209
0.234
0.732
0.594
0.719
0.979
0.549

Notes: aData are % or mean ± standard deviation. Hypertension was defined as follows: systolic blood pressure (BP) $ 140 mm Hg systolic or diastolic BP $ 90 mm Hg or
using antihypertensive treatment. P is considered significant at 0.05.

Discussion
The results of this study showed that HTN and poor GC are
major contributors to increasing the likelihood of having
MAU among Cuban Americans with T2D. The combination
and/or interaction of these factors over time might increase
the risk for progression to proteinuria/ESRD and CVD in this
population. Our findings are supported by the multicenter
study conducted in Europe that found that the likelihood of
having MAU increases in patients when HTN and poor GC
are present along with other coexisting risk factors for CVD.17
Ravid et al5 reported from their longitudinal study that a
100

combination of risk factors, including abnormal BP, plasma
cholesterol, A1c levels, high BMI, and male gender, identifies
a group of individuals for poor renal and cardiovascular
outcomes.
Maintaining adequate BP and GC is an important therapeutic goal among individuals with T2D. The UK Prospective Diabetes Study (UKPDS),18 a longitudinal study with a
10-year median follow-up, showed that exposure over time
to hyperglycemia was associated with diabetes complications
in subjects with T2D. This study also indicated that for every
1% reduction in A1c level, the risk for microvascular
complications decreased by 37% and diabetes-related
death by 21%. A study by Thomaseth et al19 showed that in

87.5%

90
80
70
60
50
40

63.9%
(P = 0.014: OR 3.96
95%CI(1.25,12.5))

Hypertensive

36.1%

Normotensive

30
20

12.5%

10
0

MAU +

MAU −

Figure 1 Unadjusted odds ratios (OR) for microalbuminuria (MAU) among
hypertensive Cuban Americans with poor glycemic control.a
Note: aP is considered significant at 0.05.

38

submit your manuscript | www.dovepress.com

Dovepress

Table 2 Likelihood of having microalbuminuria among Cuban
Americans with poor glycemic controla
Parameter

OR

95% CI for OR

P value

Hypertensive
Normotensive

6.76
1.08

1.83 to 25.01
0.30 to 3.93

0.004
0.899

Notes: aHypertension by glycemic control interaction X2 (1, n = 179) = 4.05,
P = 0.044. Controlled variables included in the logistic regression analysis were
age, gender, body mass index, known duration of diabetes, total cholesterol levels,
diabetes and cholesterol medications, smoking, total kcal and protein intakes, and
intakes of potassium, phosphorous, and sodium. P is considered significant at 0.05.
Abbreviations: CI, confidence interval; OR, odds ratio.
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hypertensive T2D subjects with incipient diabetic
nephropathy, both tight BP control and optimal GC delay
the progression of glomerular filtration rate deterioration.
Additionally, hypertensive individuals with T2D under tight
BP control experience a reduction in risk for microvascular
and macrovascular complications.20
The mechanism and pathways involving MAU with
diabetic nephropathy and CVD are not fully understood.
They may be interrelated with endothelial dysfunction and
inflammation.21 Stehouwer et al22 examined the relationship
between endothelial dysfunction and inflammation with
MAU and risk of death in a prospective study among subjects
with T2D. The results of that study showed that those participants with MAU, endothelial dysfunction, and inflammation had an increased risk in mortality; however, the
associations of these variables with risk of mortality were
independent from each other. Hyperglycemia and obesity
were associated with an increase in markers of endothelial
dysfunction and inflammation activity,22 possibly indicating
that the combinations of these factors may be interrelated in
increasing the risk of death.
The usual course of MAU is progressive; however, not
a l l T 2 D i n d iv i d u a l s w i t h M AU w i l l d ev e l o p
macroalbuminuria. Several authors have documented
remission and/or regression of MAU in subjects with
T2D. 23–27 Antihypertensive therapy has been shown to
reduce or slow the progression of diabetic nephropathy.
In a 6-year prospective study, remission and regression to
normoalbuminuria were observed in about 50% of T2D
individuals.23 Other factors independently linked with
remission and/or regression of MAU were proper BP and
GC and short duration of MAU. The study by Chan et al24
with a 5-year mean follow-up of T2D patients with MAU
treated with angiotensin-converting enzyme (ACE) inhibitor medications showed a 13% reduction in urinary albumin excretion (UAE). In addition, the authors pointed out
the main role that BP and GC play in renal function.
T2D individuals treated with angiotensin receptor blockers
(ARBs) (eg, irbesartan and valsatran) experienced a
38% and 44% reduction in UAE over 2-year and 6-month
follow-ups, respectively.25,26 Evidence from another prospective study with a 7.8-year follow-up indicated that
30% of the participants on antihypertensive therapy
achieved remission to normoalbuminuria.27 Additionally,
the odds for remission to normoalbuminuria increased in
these participants with every 1% decrease in A1c level.
Furthermore, in a study conducted by Mogensen et al,28
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urinary albumin:creatinine ratio was decreased by 50%
after a 3-month combination treatment with ARB and ACE
inhibitors in hypertensive T2D individuals with MAU.
Remission and/or regression of MAU may not only conserve renal function but also reduce the risk of CVD.
MAU is one of the earliest clinical signs of renal
impairment. Testing for MAU has been recommended by the
ADA in individuals with T2D to be performed at diagnosis
of diabetes and every year afterwards.29 The ImmunoDip
dipstick is a rapid and easy screening test to perform, does
not involve equipment and/or skilled personnel, exhibits a
high sensitivity, requires only a random urine sample (first
morning urine is recommended), and has a relatively low cost.
However, this test does not quantify urinary albumin values
and requires confirmation with a secondary analysis. This
method can be used in a physician’s office and/or research
setting as a first screening tool to detect the presence of MAU.
The clinical significance of early screening and monitoring
for MAU is possibly to improve individuals’ prognosis for
microvascular and macrovascular complications, especially
among T2D individuals with other concomitant conditions.

Limitations of the study
First, due to the cross-sectional design of the study, singlevoided urine was collected to measure MAU, and we were
not able to determine the cause–effect relationship between
the variables. Second, due to the relatively small sample size
in this study, our sample of Cuban Americans with T2D is
not representative of the entire Cuban American population
living in the USA. Nevertheless, to our knowledge, this is
the first and only study that has examined the relationship
between MAU, HTN, and GC in this Hispanic subgroup,
which has an increased risk for T2D and CVD.

Conclusion
Early detection of MAU in this population may provide more
valuable treatment and improve individuals’ renal and CVD
outcomes. The therapeutic goals and strategies for MAU
should focus on preventing long-term complications associated with T2D, such as kidney and heart diseases. Further
investigations need to be carried out to fully understand the
mechanism and absolute CVD risk that an individual with
T2D has when MAU coexists with other comorbidities.
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